Abstract
AbstractCurrent antipsychotics are useful in treating schizophrenia but do not offer a complete solution to managing the illness. Recent research suggests that modifying targets upstream of dopamine receptor blockade may hold the key to an improved psychopharmacological approach, explained Dr Oliver Howes, Honorary Consultant Psychiatrist at the South London and Maudsley NHS Foundation Trust, speaking at a satellite symposium organised by Roche at the 12th Latest Advances in Psychiatry meeting in London in March. Steve Titmarsh reports.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
